Vertex Pharmaceuticals (VRTX) reachead $475.49 at the closing of the latest trading day, reflecting a -1.41% change compared to its last close.

Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex ...

Learn more about whether Alkami Technology, Inc. or Vertex, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Vertex Pharmaceuticals Inc. closed 8.54% short of its 52-week high of $519.88, which the company achieved on November 8th.

Vertex Pharmaceuticals has grown from a $7.5 billion market cap to over $120 billion as it’s commercialized several products.

Vertex Pharmaceuticals is diversifying from its cystic fibrosis dominance into pain and other markets. Check out our ...

Shares of Vertex have rallied, even amid the broader stock market sell-off. The company is diversifying beyond its dominance in cystic fibrosis treatments. Several catalysts in 2025 support a ...

Jim Cramer continues to show his support for the biotech company, as evident by his most recent comments from the 14 th of ...

Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex Pharmaceuticals (NASDAQ: VRTX). Compared to the S&P 500 index, which is down about ...

The stock's rise snapped a three-day losing streak.